Program
Platinum Compounds
Also written as “QLS5132; Platinum; Bevacizumab”, “HS-10502 + Platinum + Bevacizumab” and “Platinum”.
Its studies are mostly in Stomach Neoplasms · Ovarian Neoplasms · Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Head and Neck Neoplasms, led by 5 companies.
Drug pagePlatinum Compounds: every studyMany companies study it; this page follows only the 5 they lead. All 26 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 10 open or running | phase 1since Jun 24, 2016 | Jun 24, 2016 | none ahead |
| Eli Lillyits history only | 10 open or running | phase 2since Jun 1, 2005 | Jun 1, 2005 | none ahead |
| Hansoh Pharmaceutical Groupits history only | 11 open or running | phase 1since Jan 7, 2025 | Jan 7, 2025 | none ahead |
| Merck KGaA, Darmstadt, Germany | 10 open or running | phase 3since Jul 19, 2005 | Jul 19, 2005 | none ahead |
| Qilu Pharmaceuticalits history only | 11 open or running | phase 2since Mar 1, 2026 | Mar 1, 2026 | Apr 2027phase 2 · NCT07453394 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck KGaA, Darmstadt, Germany only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 19, 2005First study: phase 3 study in Head and Neck NeoplasmsFirst studyNCT00122460 · 442 enrolled · Austria, Belgium, Czech Republic and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Merck KGaA, Darmstadt, Germany leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00122460Head and Neck Neoplasms · Austria, Belgium, Czech Republic and more | 3 | Completed | Mar 2007 | 442 |
How it is read
Names in the registry
- “QLS5132; Platinum; Bevacizumab”, 1 entry
- “HS-10502 + Platinum + Bevacizumab”, 1 entry
- “Platinum”, 1 entry
- “Cetuximab + platinum + gemcitabine”, 1 entry
- “Platinum + Gemcitabine”, 1 entry
Conditions, from the studies’ own filings
- Stomach Neoplasms, 1 study
- Ovarian Neoplasms, 1 study
- Small Cell Lung Carcinoma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Head and Neck Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.